減価償却費、減損損失 - 医薬品開発支援、貸倒引当金繰入額他1件
- 【期間】
| 年度 | 減価償却費 | 減損損失 - 医薬品開発支援 | 貸倒引当金繰入額 | 法人税 |
|---|
| 2008/03 | - | | - | | - | | 13.5億 | |
| 2009/03 | - | | - | | - | | 13.9億 | +3.1% |
| 2010/03 | - | | - | | - | | 15.8億 | +13.8% |
| 2011/03 | - | | - | | - | | 17.2億 | +8.9% |
| 2012/03 | - | | - | | - | | 15億 | -13.1% |
| 2013/03 | 69百万 | | - | | - | | 16億 | +6.9% |
| 2014/03 | 38百万 | -45% | - | | - | | 18.5億 | +15.7% |
| 2015/03 | - | | 139百万 | | - | | 24.6億 | +32.8% |
| 2016/03 | - | | - | | - | | 12.6億 | -48.8% |
| 2017/03 | - | | - | | - | | 15億 | +18.9% |
| 2018/03 | - | | - | | - | | 13億 | -13.1% |
| 2019/03 | - | | - | | - | | 14.1億 | +8.3% |
| 2020/06 | - | | - | | - | | 13.8億 | -2% |
| 2021/06 | - | | - | | 208百万 | | 14.9億 | +7.9% |
| 2022/06 | - | | - | | 80百万 | -61.8% | 16.4億 | +10.2% |
| 2023/06 | - | | - | | 307百万 | +286.2% | 15.1億 | -8.3% |
